PYC Therapeutics says fourth candidate has potential in polycystic kidney disease

November 13, 2023 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

PYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimensional human models derived from patients with end-stage renal failure due to autosomal dominant polycystic kidney disease. …

Subscribe now to continue reading.

Latest Video

The lesson to learn from the Guild is that you cannot defeat what you do not know
December 14, 2025 - Latest News
Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis
December 15, 2025 - Latest News
Algorae unveils major breakthrough in AI-driven drug combination discovery
December 14, 2025 - Australian Biotech
GBMA to host inaugural summit aimed at addressing medicine shortages
December 15, 2025 - Latest News
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - Latest News

PYC Therapeutics says fourth candidate has potential in polycystic kidney disease

This is a preview of subscriber content

Latest Video

Most Read

The lesson to learn from the Guild is that you cannot defeat what you do not know

Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis

Algorae unveils major breakthrough in AI-driven drug combination discovery

GBMA to host inaugural summit aimed at addressing medicine shortages

The industry is probably right to resist, it just needs to prepare for the response

New Stories

Island Pharmaceuticals secures key partnership with Texas Biomed

Novartis names new Country President following leadership transition

Mayne Pharma opens expanded manufacturing facility after termination of takeover

Budget update includes impact of listings, but generally not much else

The UK reconfirms the direct impact of the transatlantic shift in medicine pricing

The industry is probably right to resist, it just needs to prepare for the response

Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy

Sign In

PYC Therapeutics says fourth candidate has potential in polycystic kidney disease

This is a preview of subscriber content

Latest Video

Most Read

The lesson to learn from the Guild is that you cannot defeat what you do not know

Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis

Algorae unveils major breakthrough in AI-driven drug combination discovery

GBMA to host inaugural summit aimed at addressing medicine shortages

The industry is probably right to resist, it just needs to prepare for the response

Follow Us

New Stories

Island Pharmaceuticals secures key partnership with Texas Biomed

Novartis names new Country President following leadership transition

Mayne Pharma opens expanded manufacturing facility after termination of takeover

Budget update includes impact of listings, but generally not much else

The UK reconfirms the direct impact of the transatlantic shift in medicine pricing

The industry is probably right to resist, it just needs to prepare for the response

Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy